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Abstract 
 
Primary ciliary dyskinesia (PCD) has been considered to be relatively mild disease, especially 
compared to cystic fibrosis (CF), but studies on lung function in PCD patients have been few 
and small.  
This study compared lung function from spirometry of PCD patients to normal reference values 
and to published data from CF. We calculated z-scores and percentage of predicted values for 
FEV1 and FVC using the Global Lung Function Initiative 2012 for 991 patients from the 
international PCD (iPCD) Cohort. We then assessed associations with age, sex, country, 
diagnostic certainty, organ laterality, body mass index and age at diagnosis in linear regression 
models. Lung function in PCD patients was reduced compared to reference values in both 
sexes and all age groups. Children aged 6-9 years had the smallest impairment (FEV1 z-score -
0.84 [-1.03 to -0.65], FVC z-score -0.31 [-0.51 to -0.11]). Compared to CF patients, FEV1 was 
similarly reduced in children (age 6-9 years PCD, 91% [88–93%]; CF, 90% [88–91%]), but less 
impaired in young adults (age 18-21 years PCD, 79% [76–82%]; CF, 66% [65–68%]). The 
results suggest that PCD affects lung function from early in life, which emphasizes the 
importance of early, standardised care for all patients. 
 
Keywords: Primary Ciliary Dyskinesia, lung function, retrospective cohort, epidemiology, 
orphan diseases 
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INTRODUCTION 
Primary ciliary dyskinesia (PCD) is a multiorgan disease which is genetically and clinically 
heterogeneous [1,2]. PCD affects approximately 1:10,000 people, and it is often 
underdiagnosed or diagnosed late [3,4]. Due to abnormal ciliary function in PCD, mucus is not 
properly cleared from the airways [5], resulting in chronic lung disease. For many years, PCD 
was considered a relatively mild disease [6], particularly when compared to cystic fibrosis (CF).  
Findings on lung function of PCD patients in previous studies are inconsistent. Children with 
PCD from six North American centres were found to have normal spirometric indices, with a 
median forced expiratory volume in the first second (FEV1) of 89% predicted [7]. In contrast, a 
Belgian study reported that 112 patients with PCD already had abnormal FEV1 and forced vital 
capacity (FVC) from the age of five [8]. Recent studies, particularly in adults, have reported 
considerable heterogeneity among patients [9-11]. A recent systematic review of 24 studies [12] 
found that FEV1 of patients with PCD ranged from 44 to 69% predicted. Most studies were 
small, with an average of 40 patients per study. While risk factors for lung function impairment 
have been studied in many respiratory diseases, this has not been done for PCD. 
Using data from the international PCD (iPCD) Cohort [13], we assessed lung function in patients 
with PCD and compared it to Global Lung Function Initiative (GLI) 2012 reference values [14], 
and to published lung function data of patients with CF [15]. We investigated possible 
determinants of lung function including sex, age, situs anomalies, body mass index (BMI), 
country of residence, ultrastructural defect and level of diagnostic certainty. We also assessed 
whether age at diagnosis in paediatric patients is associated with lung function later in life.  
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METHODS 
Study population and study design 
The iPCD Cohort is a large, retrospective international cohort initiated during the EU FP7 project 
Better Experimental Screening and Treatment for Primary Ciliary Dyskinesia (BESTCILIA) and 
further developed through COST-Action network BEAT-PCD [16]. It includes international 
information on diagnostic test results, clinical symptoms, growth, lung function, and treatment 
for over 3200 patients [13]. For this study, we included all patients whose datasets had been 
delivered, cleaned, and standardised by the time of analysis (April 2016), and for whom, we had 
information on FEV1 and FVC. Participating centres were requested to only deliver lung function 
data of clinical stable patients from scheduled follow-up visits. Principal investigators were 
responsible for obtaining ethics approval and informed consent in their countries to contribute 
observational, anonymised data. 
PCD diagnosis 
PCD diagnostics remains challenging and has evolved over the years [17]. Recent guidelines 
recommend a combination of tests [18], but test availability differs between countries [19]. In the 
iPCD Cohort, we divided patients into three subgroups based on diagnostic tests. The first 
subgroup includes patients with definite PCD defined, according to recent guidelines of the ERS 
PCD Diagnostics Task Force [18], as patients with a clinical phenotype consistent with PCD and 
a hallmark transmission electron microscopy (TEM) finding, and/or pathogenic biallelic PCD 
genetic mutations. The second subgroup, probable PCD, includes patients with a clinical 
phenotype consistent with PCD and abnormal high-speed video microscopy findings and/or low 
nasal nitric oxide and a clinical phenotype consistent with PCD. The third subgroup includes 
patients with clinical phenotypes consistent with PCD diagnosis in whom other possible 
diagnoses such as CF were excluded. In most of these patients the diagnostic algorithm was 
not complete due to test unavailability (e.g. genetic testing was not available for most centres). 
The online supplement describes details of diagnosis.  
Lung function measurements 
We calculated FEV1 and FVC z-scores adjusted for age, sex, height, and ethnicity, and 
%predicted values using the GLI 2012 reference values [14]. We excluded data from children 
who were younger than 6 years to ensure better measurement quality and comparability with 
the published CF data [15].We included one lung function measurement per patient in the 
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analysis. For patients with multiple measurements, we used the measurement recorded at the 
youngest age. 
Determinants of lung function 
We investigated the association of lung function with sex, age, country of residence, level of 
diagnostic certainty, organ laterality, BMI and ultrastructural defect at time of lung function 
measurement. Details on how we categorised the selected variables and why we chose them 
are available in the online supplement. 
Comparison to CF patients  
To compare with CF patients, we used recently published data of 5904 patients with CF from 
the United Kingdom [15], which described %predicted values for FEV1 and FVC, instead of z-
scores. Thus we analysed our PCD data in the same way to allow for a direct comparison. For 
this analysis, we stratified the data by age without further adjustment.   
Statistical analysis 
We compared included patients with those who were excluded due to the absence of lung 
function measurements using chi-square tests. We compared FEV1 and FVC to the GLI 
reference values, and investigated potential determinants of lung function including sex, age, 
country, and diagnostic certainty using multivariable linear regression models with z-scores as 
dependent variable. We tested for differences in FEV1 and FVC between patient groups by 
performing likelihood ratio (LR) tests. We coded categorical predictor variables included in 
regression models using weighted effect coding. Estimated parameters for a given category 
thus represent mean z-score differences from the population mean [20,21]. In separate 
regression models including patients with available data and adjusting for the same variables, 
we assessed the association between BMI, organ laterality and ultrastructural defect with FEV1 
and FVC. In a separate model applied to our paediatric population, we assessed whether age at 
diagnosis influenced lung function later in life. We received date of diagnosis from the centres or 
calculated it from the dates of diagnostic test results. In patients without positive diagnostic test 
results, we defined date of clinical diagnosis as the date of the first clinical follow up. For this 
analysis, we only included children that had lung function measurements available after 
diagnosis (N=167) to ensure that they were already under PCD management at lung function 
measurement. We included all patients diagnosed with PCD between birth and the age of 15 
years who had at least one available lung function measurement between the ages 15 and 20 
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years (Figure S2). We categorised age at diagnosis in 3 groups: 0-5 (N=36), 5-10 (N=65), and 
10-15 (N=65) years. We performed two sensitivity analyses to test the robustness of findings, 
the first by including only patients with definite PCD diagnosis [18], and the second by including 
the latest recorded lung function measurement for patients with multiple recorded 
measurements, instead of the earliest. We used STATA 14.1 and R 3.1.2 for all analyses. 
 
RESULTS 
Population characteristics 
Twenty-one centres had delivered cleaned and standardised data from 2667 patients by the 
time of analysis (April 2016). After exclusion of patients aged younger than 6 years and those 
with no lung function data or information insufficient to calculate z-scores, we included 991 
patients in the main analysis (figure S1). Characteristics of the main study population are given 
in table 1, while table S2 compares included and excluded patients. 
In total, 62% of included patients were designated as definite PCD, 21% as “probable” PCD, 
and 17% as having only a clinical diagnosis (Table 1). Most patients had been diagnosed during 
childhood. Included patients differed from those excluded because of insufficient data to 
calculate lung function z-scores by age and country of residence, and from those excluded due 
to the lack of lung function data by sex and country of residence (Table S2). 
FEV1 and FVC in patients with PCD  
Mean FEV1 and mean FVC were lower than the mean reference values in all age groups. 
Among all patients, 46% had an FEV1 z-score below the lower limit of normal (LLN) of -1.645 
and 28% had an FVC z-score below the LLN. Impairment differed between age groups (table 2, 
figure 1). Children aged 6-9 years had the best lung function and adults the worst. Results 
differed between countries. PCD patients had lower FEV1 z-scores than reference data in all 
countries and lower FVC z-scores in most countries (Table 2, Figure 2), but patients in Belgium, 
France, Italy, and the Netherlands had on average better FVC z-scores than rest of the study 
population and were comparable to the GLI reference values. Female patients had lower FEV1 
z-scores than male patients (Table 2, Figure 3), but their FVC was comparable. FEV1 and FVC 
z-scores did not differ by levels of diagnostic certainty, and there was no evidence of 
association with organ laterality (Figure 3 and Table S3). BMI was positively associated with 
FEV1 and FVC: patients who were underweight had worse lung function than normal and 
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overweight patients (Figure 3 and Table S4). FEV1 z-scores differed between ultrastructural 
defect groups, patients with a micro tubular defect had worse lung function than patients with a 
non-diagnostic TEM and patients with outer or inner dynein arm defects (Table 3). Sensitivity 
analyses that included only patients with a definite PCD diagnosis (611 patients) had similar 
results for FEV1 and FVC to the original models (Tables 2 and S5). When we included the latest 
recorded lung function measurement for patients with multiple available values instead of the 
earliest available, results were similar to the original models (Tables 2 and S6).  
Age at diagnosis was not significantly associated with lung function in 167 patients aged 15-20 
years. Among them, the children diagnosed between the age of 5-10 years had better lung 
function compared to those diagnosed at 10-15 years, differences however were small and not 
statistically significant (Figure S3). 
Lung function in patients with PCD compared to patients with cystic fibrosis 
Both PCD and CF patients had impaired spirometric indices (Figure 4). Average FEV1 and FVC 
values of children with PCD who were under 17 were low and similar to children with CF. During 
adolescence and early adulthood measurements began to diverge and older patients with PCD 
had better lung function than CF patients. Though differences in FEV1 and FVC persisted 
between PCD and CF patients, after the age of 30, the differences narrowed. 
DISCUSSION 
This multinational study found that lung function of patients with PCD was considerably lower 
than reference values. All age groups, including young children and patients from most 
countries had reduced FEV1 and FVC z-scores. Female sex, underweight and type of 
ultrastructural defect were predictors of worse lung function. Results were consistent in all 
diagnostic and organ laterality subgroups. In children and adolescents, lung function of patients 
with PCD was similar as for CF patients. Our data therefore refute the traditionally-held 
assumption that PCD is a relatively mild disease. 
This is the largest multi-centre study on lung function in patients with PCD. The large study 
population enabled us to study differences in FEV1 and FVC between males and females, age 
groups, countries, and levels of diagnostic certainty. A potential limitation of our study is that the 
iPCD Cohort includes mainly patients from centres with developed diagnostic facilities. 
Therefore smaller centres and some countries are underrepresented. Also, we had no data on 
infection status at time of measurement, such as chronic colonisation with Pseudomonas. In our 
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analysis we only included stable patients measured at scheduled follow-up visits. Only a 
prospective study could investigate this association, because surveillance of infections varies 
between countries and centres. Centres which routinely assess microbiology are more likely to 
detect pathogens than centres, which check patients when they are unwell. A limitation of the 
comparison with CF patients was that CF patients came from the UK only, and their lung 
function was compared using Wang-Hankison reference values; while we used GLI references 
for the PCD patients. However, differences between the two references are minimal [15,22]. In a 
sensitivity analysis we compared our PCD population to FEV1 %predicted values based on GLI 
reference published in the 2016 annual data report of UK CF Registry and found similar results 
(Figure S4). 
Previous studies examining lung function in patients with PCD included rather small selected 
patient groups from single centres and have yielded inconsistent results [12]. Our findings 
strongly suggest that lung function in patients with PCD is already reduced early in life. Different 
mechanisms could contribute, including reversible causes such as temporary atelectasis and 
mucus plugging [23], and irreversible damage such as lung remodelling after recurrent severe 
infections during the period of lung growth [24]. Our data also suggest that lung function in 
adulthood remains impaired. Some recent studies are in line with our findings. A study of 118 
adult patients from the UK [11] and a multi-centre study including 158 children and adults from 
UK, Italy and Denmark [25] both reported reduced FEV1 and FVC, in patients with PCD. Lung 
function in 168 patients from Belgium was already reduced at the age of 5 years, but there was 
no evidence of a difference in FEV1 and FVC z-scores between age groups [8]. The wide 
variation between different countries, which we found, could reflect variations in genotype, in 
age at diagnosis [4], in management [26] or in appropriateness of the GLI reference values for 
the different countries.  
We found that females had a poorer lung function than males (FEV1 z-scores females -1.57, 
males -1.36). Although other studies have reported similar sex differences in PCD [9,27] and CF 
[28], the processes that affect lung function particularly in women are not well understood. It 
could reflect treatment variation, differences in therapy adherence, or anatomical, hormonal, or 
cultural causes. The female sex hormone progesterone is known to inhibit the function of the 
mucociliary apparatus and could contribute to the sex disparity [29].  
We found also a strong association between lung function and BMI, thus confirming previous 
results from an overlapping dataset [30]. Data on BMI and lung function in PCD patients from 
other studies are inconsistent. The multi-centre study of 158 children found no correlation 
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between BMI and FEV1 z-scores [25], while a study of 34 patients from Israel reported a 
borderline correlation between FEV1 and BMI in patients with PCD [31]. It has repeatedly been 
shown that nutritional input can influence outcomes in chronic respiratory diseases [32]. 
Reduced BMI could be the result of increased energy spending because of an increased 
respiratory effort, or nutritional intake could lead to both lower BMI and poor lung function [33]. 
Lastly, purulent lung disease can negatively affect appetite and nutrition status [34]. Information 
on the direction of association, i.e. whether BMI influences lung function or lung function 
influences BMI, can only be taken from longitudinal studies with repeated measurements of both 
parameters. However, as intensive nutritional input from an early age has contributed to 
reduced mortality in CF patients in recent years [35,36] it should also be considered in PCD 
treatment regimens.  
We found that patients with microtubular ultrastructural defects had a lower FEV1 compared to 
the other patients. Our findings are in line with other recent studies, where patients with 
microtubular defects had worse lung function measured with spirometry or breath wash-out 
techniques, than patients with outer and inner dynein arm defects [7,11,37]. The mechanisms 
leading to differences in lung function based on the underlining ultrastructural defect are not 
understood. The findings however show a possible link between the genotype and 
ultrastructural phenotype with the clinical manifestations, possible due to differences in 
mechanics of impaired cilia movement. Adequate diagnostic evaluation could provide important 
information to understand severity and prognosis in PCD. 
Studies have reported contradictory results about associations between age at diagnosis and 
lung function of PCD patients. Some studies reported that regular treatment can maintain lung 
function [25,38,39], and early diagnosis may prevent progression of lung disease [27]. However, 
other studies reported no association between age at diagnosis and decline in lung function 
[10,11]. We did not see evidence that early diagnosis is associated with better lung function in 
adolescents. An explanation, other than the relatively small subgroup sample, could be that 
patients with milder disease and thus with better lung function are diagnosed later in life than 
patients with more severe disease. Another possibility is that our studied differences in age of 
diagnosis might not have been large enough to have a measurable effect on spirometry. 
Longitudinal studies with more sensitive outcome measures will be necessary to shed further 
light on the importance of early diagnosis and disease management in patients with PCD. 
Comparisons of lung function between PCD and CF are rare and the results have been unclear. 
Some studies concluded that FEV1 was similar in PCD and CF patients [31,40,41], while 
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another one reported that it was lower in PCD children compared to pancreatic sufficient and 
insufficient CF children [42]. Yet another study found that children with PCD had better FVC but 
similar FEV1 than children with CF [43]. But all these studies had low numbers and might not be 
representative of the average patient with PCD. Our findings from a large multinational dataset 
suggest that lung function in PCD patients is comparable to that of CF patients in childhood, but 
better in young adulthood. This may suggest that patients with CF have a worse disease course 
than patients with PCD because they have a more aggressive lung disease. Many of the 
younger CF patients might have been diagnosed via newborn screening, before they developed 
respiratory symptoms, while older CF patients have been diagnosed later, after initial lung 
damage has occurred. Patients with PCD in our study have all been diagnosed late, sometimes 
years or decades after the presentation of symptoms [4,11]. This could explain the similar lung 
function for CF and PCD patients early in life despite a more severe disease course in CF. It 
could also be that children with PCD are treated less effectively early in life than those with CF 
due to the lack of evidence-based treatment recommendations. But it also could be that patients 
already diagnosed with PCD in childhood have a worse disease course and thus lower lung 
function than patients diagnosed later in life. The decline of lung function by age was steeper in 
young adults with CF, and seemed to plateau in middle-aged patients in both diseases. This 
stabilization of impaired lung function in middle age and older patients might be an effect of 
mortality or lung transplantation; the surviving patients could be those with a less severe 
disease course. Unfortunately, there are few data on mortality in patients with PCD [24]. 
Longitudinal data would allow the evaluation of changes in lung function over time and the 
identification of predictors of poor lung function later in life. This could assist finding strategies to 
delay lung function impairment and disease progression. 
In conclusion, although PCD has been considered a relatively mild disease, this study suggest 
that it affects lung function from an early age similarly to CF. This and the significant variation in 
PCD across countries emphasise the importance of early, multidisciplinary, standardised care 
and evidence-based treatments for all patients with PCD. 
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METHODS 
 
Primary ciliary dyskinesia diagnosis 
The diagnostic criteria for PCD have evolved over many years [1]. Initially, diagnosis was based on 
the Kartagener triad [2] and transmission electron microscopy findings (EM).Then, light microscopy 
and, later, high frequency video microscopy (HVM) were introduced into the diagnostic algorithm. 
Recent recommendations include combining EM, HVM, nasal nitric oxide (nNO), and genetic testing 
[3], but availability of tests differs between countries [4] so not all PCD patients have been 
diagnosed according to current standards. Patients diagnosed years ago and patients who live in 
countries with limited resources are least likely to have been diagnosed according to these 
recommendations. The iPCD Cohort includes patients diagnosed since 1964, so we divided patients 
into three diagnostic subgroups based on the results of the tests available. The first subgroup 
included patients with definite PCD defined, based on recent guidelines of the ERS PCD 
Diagnostics Task Force [3], as hallmark EM findings and/or pathogenic biallelic PCD genetic 
mutations. The second subgroup, probable PCD, included patients with abnormal HVM findings 
and/or low nNO (we used a cut-off of 77nl/min [5]). The third subgroup included patients with clinical 
PCD diagnosis; these were patients for whom the PCD diagnostic algorithm had not yet been 
completed, or whose test results were negative or ambiguous. Patients in this latter group were 
followed up and treated as PCD at the collaborating centres based on a combination of several of 
the following features: situs anomalies, persistent cough, persistent rhinitis, chronic or recurrent 
upper or lower respiratory infections, and history of neonatal respiratory symptoms in term infants 
[3]. Other possible more common diseases such as cystic fibrosis and immunodeficiency were 
excluded. 
 
FEV1 and FVC 
We checked data quality to identify outliers and implausible values, and contacted data contributors 
to resolve any unclear issues. We used the Global Lung Function Initiative (GLI) reference values to 
calculate age, sex, ethnicity, and height-adjusted z-scores of forced expiratory volume in one 
second (FEV1) and forced vital capacity (FVC) [6].  
 
 
  
Determinants of lung function 
We investigated the association of lung function with sex, age, country of residence, level of 
diagnostic certainty, organ laterality, BMI, and ultrastructural defect at time of lung function 
measurement. Despite having calculated age, height, and sex-specific z-scores, impairment of lung 
function might differ between male and female PCD patients. Analysis of different age groups helps 
to find whether PCD affects lung growth in children, or whether it accelerates lung function decline 
in adults. To facilitate comparison with available published cystic fibrosis (CF) data [7], we 
categorised patients into the same 12 age groups (6-9, 10-13, 14-17, 18-21, 22-25, 26-29, 30-33, 
34-37, 38-41, 42-45, 46-49 and ≥50 years). Patients with situs inversus might have less severe 
disease because they are diagnosed and treated earlier, sometimes even before symptoms develop 
[4]. We categorised organ laterality into three groups (situs solitus totalis, situs inversus, and 
heterotaxia). BMI as an indicator of nutrition has been associated with lung function in many chronic 
respiratory diseases. We identified national growth references by contacting collaborating centres 
and searching the literature. For each centre, we chose one of the following methods to calculate z-
scores based on national references: 1) an LMS approach using tables that contained L, M, and S 
parameters needed to generate exact z-scores [8]; 2) direct calculation via online national z-score or 
percentile growth calculators; or 3) interpolating exact z-scores from plotted percentile boundaries 
on growth curves. Available references for BMI were intended for use with children only. For 
paediatric patients aged <18 years, we calculated age- and sex-adjusted BMI z-scores based on 
available reference values, preferably national where they were available (the sources are listed in 
the online supplement, Table S1), and we defined underweight as a BMI z-score less than or equal 
to -1.96, and overweight as a BMI z-score ≥1.96. For patients aged ≥18 years we used the WHO 
international BMI classification for adults, which define underweight as BMI < 18.5 and overweight 
as BMI ≥ 25.0 [9]. Differences between countries could show ethnic variations, or differences in age 
at diagnosis or disease management. We categorised ultrastructural defects into non-diagnostic, 
dynein arm defects (outer and/or inner dynein arm defects), microtubular defects (central pair, 
tubulus disorganisation, tubular transposition and/or nexin link defect), and acilia. 
  
Table S1. National references used for calculations of BMI z-scores 
Country  Growth reference source Year of publication 
Australia Centre for Disease Control and Prevention [10] 2000 
Belgium Flemish growth study (Roelants et al.) [11] 2009 
Cyprus Growth curves for Greek children 0-5 years (Papadimitriou et al.) 
[12] 
Growth curves for Cypriot children 6-17 years (Savva et al.) [13] 
2000 
2001 
Denmark Danish growth references (Tinggaard et al.) [14] 2014 
France French references for Height (Sempé et al.) [15] 
French references for BMI (Rolland-Cachera et al.) [16] 
1979 
1991 
Germany KiGGS study [17] 2006 
Israel Centre for Disease Control and Prevention [10] 2000 
Italy Centre for Disease Control and Prevention [10] 2000 
Netherlands Fifth Dutch Growth Study [18] 2009 
Norway Growth charts for Norwegian children (Júlíusson et al.) [19] 2009 
Poland Growth references (Kulaga et al.) [20] 2010 
Serbia Not available* - 
Switzerland Swiss growth curves (Braegger et al.) [21] 2011 
Turkey Growth references for Turkish children (Neyzi et al.) [22] 2006 
United Kingdom Royal College of Paediatrics and Child Health [23,24] 1990 
* No national growth references were available in Serbia, for which the WHO references are used instead. Table adapted from 
Goutaki et al. [25] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S1. Flow chart showing the patients included for the different analyses performed. 
 
  
Insufficient information to 
calculate z-scores 
(N=981) 
 Data of patients ≥6 years old 
(N=2491 from 19 centres) 
Patients with definite 
PCD diagnosis  
(N=611) 
Patients included in 
analysis of BMI 
 (N=920) 
Patients included in main analyses  
(N=991) 
 
 Data delivered and standardised 
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Figure S2. Study design on patient inclusion to assess the association of age at diagnosis with lung 
function. 
 
  
 
Fig S3. FEV1 and FVC in PCD patients aged 15 to 20 years by age of diagnosis compared to GLI 
2012 reference values. FEV1 and FVC are presented as mean z-score (95%CI). 
  
 
Fig S4. Association of FEV1 of PCD patients with CF patients using GLI 2012 references values. 
FEV1 of PCD patients are presented as mean %predicted and 95%CI, and FEV1 of CF patients are 
presented as mean, without adjusting for other factors. The dashed line shows the mean of the 
normal population.  
  
Table S2. Characteristics of PCD patients included in this study compared to those who were excluded 
Characteristic Study 
Participants 
 
(n=991) 
Insufficient 
information 
on lung 
function 
(n=981) 
Comparison 
with 
participants 
p-value¶ 
No lung 
function data 
contributed 
(n=519) 
Comparison 
with 
participants 
p-value¶ 
 n (%) n (%)  n (%)  
Sex   0.91  0.01 
Male 487 (49)  481 (49)  290 (56)  
Female 504 (51) 491 (50)  228 (44) 
Missing 0 (0) 9 (1)  1 (0) 
Country of 
residence* 
  <0.001  <0.001 
Australia 34 (3) 42 (4)  0 (0)  
Northern Europe 306 (31) 145 (15)  0 (0) 
Western Europe 392 (40) 731 (75)  0 (0) 
Eastern Europe 74 (7) 8 (1)  0 (0) 
Southern Europe 42 (4) 5 (1)  0 (0) 
Western Asia 143 (14) 50 (5)  0 (0) 
North America 0 (0) 0 (0)  418 (81) 
South America 0 (0) 0 (0)  101 (19)  
Current age#    <0.001  <0.001 
6-9 years 15 (2) 213 (22)  44 (8)  
10-19 years 445 (45) 354 (36)  218 (42) 
20-29 years 248 (25) 146 (15)  122 (24) 
30-39 years 129 (13) 100 (10)  34 (7) 
40-49 years  64 (6) 70 (7)  43 (8) 
>50 years 90 (9) 76 (8)  57 (11) 
Missing 0 (0) 22 (2)  1 (0)  
* Based on the United Nations Statistics Division 
¶ Chi-squared tests  
# In April 2016 
 
 
 
  
Table S3. FEV1 and FVC of PCD patients of the iPCD Cohort with available situs information 
compared to GLI 2012 references (N=860) 
    FEV1   FVC 
Characteristic N mean z-score 95% CI p-value
¶    N mean z-score 95% CI p-value
¶ 
Total 860 -1.52 -1.63 -1.41  853 -0.79 -0.90 -0.67 
 
Sex     0.10     0.51 
Male 417 -1.47 -1.62 -1.32  413 -0.75 -0.90 -0.60  
Female 443 -1.56 -1.71 -1.42  440 -0.82 -0.96 -0.67  
Age group     <0.001     <0.001 
6-9 years 164 -0.80 -1.04 -0.56  163 -0.29 -0.53 -0.05  
10-13 years 188 -1.05 -1.28 -0.83  187 -0.50 -0.72 -0.27  
14-17 years 184 -1.48 -1.71 -1.26  182 -0.77 -0.99 -0.54  
18-21 years 85 -1.58 -1.91 -1.25  85 -0.63 -0.96 -0.30  
22-25 years 60 -1.80 -2.19 -1.40  59 -0.89 -1.29 -0.49  
26-29 years 42 -2.29 -2.76 -1.82  41 -1.32 -1.80 -0.84  
30-33 years 27 -2.61 -3.19 -2.03  26 -1.42 -2.02 -0.83  
34-37 years 23 -2.75 -3.37 -2.12  24 -1.76 -2.38 -1.15  
38-41 years 14 -2.47 -3.28 -1.66  14 -1.25 -2.06 -0.43  
42-45 years 14 -3.24 -4.05 -2.42  14 -2.74 -3.55 -1.92  
46-49 years 20 -2.90 -3.59 -2.22  20 -1.95 -2.64 -1.26  
≥50 years 39 -2.41 -2.90 -1.92  38 -1.48 -1.97 -0.98  
Country     <0.001     <0.001 
Australia 34 -1.79 -2.31 -1.27  34 -1.17 -1.69 -0.65  
Belgium 69 -1.18 -1.56 -0.81  69 -0.05 -0.42 0.33  
Cyprus 27 -1.89 -2.48 -1.30  27 -1.74 -2.34 -1.15  
Denmark 72 -1.21 -1.57 -0.86  72 -0.19 -0.55 0.16  
France 11 -1.36 -2.28 -0.45  11 -0.85 -1.78 0.07  
Germany 104 -1.21 -1.51 -0.91  99 -0.64 -0.95 -0.33  
Israel 85 -1.57 -1.89 -1.24  82 -1.09 -1.43 -0.76  
Italy 35 -1.45 -1.97 -0.93  35 -0.67 -1.20 -0.15  
Netherlands 65 -0.50 -0.88 -0.12  65 0.67 0.29 1.05  
Norway 14 -1.36 -2.17 -0.56  14 -0.79 -1.60 0.03  
Poland 74 -1.93 -2.29 -1.57  74 -0.98 -1.34 -0.61  
Serbia 7 -2.34 -3.49 -1.20  7 -2.58 -3.73 -1.42  
Switzerland 29 -1.87 -2.43 -1.31  29 -1.23 -1.79 -0.67  
Turkey 29 -1.91 -2.51 -1.31  29 -1.65 -2.25 -1.04  
UK 205 -1.85 -2.07 -1.64  206 -1.16 -1.37 -0.94  
Diagnostic certainty     0.58     0.50 
Definite PCD diagnosis+ 554 -1.55 -1.68 -1.42  551 -0.78 -0.91 -0.65  
Probable PCD diagnosis# 195 -1.58 -1.80 -1.35  191 -0.88 -1.11 -0.65  
Clinical diagnosis only 111 -1.27 -1.58 -0.97  111 -0.66 -0.97 -0.34  
Situs anomalies     0.67     0.35 
Situs solitus totalis 499 -1.52 -1.66 -1.38  496 -0.83 -0.98 -0.69  
Situs inversus  348 -1.46 -1.63 -1.29  344 -0.77 -0.94 -0.59  
Heterotaxia 13 -1.82 -2.68 -0.96   13 -1.40 -2.29 -0.51   
Mean z-scores (95%CI) for each group after adjusting for the remaining characteristics 
¶ Likelihood ratio test p-value indicating whether the characteristic explains differences in FEV1 or FVC 
within the study population 
+ Defined as hallmark PCD electron microscopy findings and/or biallelic gene mutation identified based on 
the ERS PCD Diagnostics Task Force guidelines [26] 
# Abnormal light or high frequency video microscopy finding and/or low nasal NO value  
Table S4.  FEV1 and FVC of PCD patients of the iPCD Cohort with available BMI information 
compared to GLI 2012 references (N=927) 
    FEV1   FVC 
Characteristic  N mean z-score 95% CI p-value
¶ N  mean z-score 95% CI p-value
¶ 
Total 927 -1.47 -1.58 -1.37  924 -0.73 -0.84 -0.62 
 
Sex     0.08     0.31 
Male 458 -1.39 -1.52 -1.25  458 -0.68 -0.82 -0.54  
Female 469 -1.56 -1.69 -1.42  466 -0.78 -0.92 -0.65  
Age group     <0.001     <0.001 
6-9 years 182 -0.76 -0.97 -0.54  181 -0.19 -0.41 0.04  
10-13 years 220 -1.03 -1.23 -0.83  217 -0.44 -0.65 -0.24  
14-17 years 207 -1.42 -1.63 -1.22  210 -0.70 -0.90 -0.49  
18-21 years 90 -1.53 -1.84 -1.22  90 -0.56 -0.88 -0.25  
22-25 years 54 -1.75 -2.16 -1.35  53 -0.85 -1.27 -0.44  
26-29 years 37 -2.21 -2.70 -1.72  36 -1.23 -1.73 -0.72  
30-33 years 25 -2.84 -3.43 -2.25  25 -1.84 -2.45 -1.24  
34-37 years 22 -2.98 -3.61 -2.36  23 -1.85 -2.48 -1.23  
38-41 years 15 -2.72 -3.48 -1.97  15 -1.53 -2.31 -0.75  
42-45 years 14 -3.43 -4.22 -2.65  15 -2.96 -3.74 -2.18  
46-49 years 20 -3.03 -3.70 -2.36  19 -2.04 -2.75 -1.34  
≥50 years 41 -2.59 -3.06 -2.11  40 -1.66 -2.15 -1.17  
Country     <0.001     <0.001 
Australia 34 -1.73 -2.24 -1.23  34 -1.12 -1.63 -0.60  
Belgium 69 -1.14 -1.50 -0.78  69 -0.03 -0.40 0.34  
Cyprus 25 -1.73 -2.33 -1.13  25 -1.53 -2.14 -0.91  
Denmark 70 -1.15 -1.50 -0.80  70 -0.13 -0.49 0.23  
France 75 -1.45 -1.79 -1.10  72 -0.55 -0.91 -0.19  
Germany 123 -1.27 -1.54 -1.00  123 -0.68 -0.96 -0.41  
Israel 75 -1.57 -1.91 -1.23  74 -1.14 -1.48 -0.79  
Italy 35 -1.52 -2.02 -1.02  35 -0.72 -1.24 -0.21  
Netherlands 66 -0.52 -0.88 -0.15  66 0.58 0.21 0.95  
Norway 14 -1.30 -2.08 -0.52  14 -0.73 -1.52 0.07  
Poland 74 -1.90 -2.24 -1.55  74 -0.98 -1.34 -0.63  
Serbia 7 -2.39 -3.49 -1.29  7 -2.70 -3.83 -1.57  
Switzerland 40 -1.72 -2.18 -1.26  40 -0.97 -1.44 -0.49  
Turkey 29 -1.79 -2.35 -1.23  29 -1.56 -2.13 -0.98  
UK 191 -1.77 -1.98 -1.55  192 -1.09 -1.31 -0.87  
Diagnostic certainty     0.45     0.54 
Definite PCD diagnosis+ 574 -1.50 -1.62 -1.37  574 -0.73 -0.86 -0.60  
Probable PCD diagnosis# 191 -1.53 -1.74 -1.31  190 -0.82 -1.05 -0.60  
Clinical diagnosis only 162 -1.33 -1.58 -1.09  160 -0.64 -0.89 -0.38  
BMI     <0.001     <0.001 
Underweight 59 -2.54 -2.92 -2.16  60 -1.94 -2.33 -1.55  
Normal 752 -1.48 -1.58 -1.37  750 -0.74 -0.85 -0.63  
Overweight 116 -0.91 -1.20 -0.62   114 -0.07 -0.37 0.23   
 Mean z-scores (95%CI) for each group after adjusting for the remaining characteristics 
¶ Likelihood ratio test p-value indicating whether the characteristic explains differences in FEV1 or FVC 
within the study population 
+ Defined as hallmark PCD electron microscopy findings and/or biallelic gene mutation identified based 
on the ERS PCD Diagnostics Task Force guidelines [26] 
# Abnormal light or high frequency video microscopy finding and/or low nasal NO value; patients from Serbia were 
excluded from this analysis as there are no available national references  
Table S5. FEV1 and FVC of PCD patients of the iPCD Cohort with a definite PCD diagnosis 
compared to GLI 2012 references (sensitivity analysis) (N=611) 
   FEV1   FVC 
Characteristic N mean  z-score 95% CI p-value¶ N 
mean 
z-score 95% CI p-value¶ 
Total 611 -1.54 -1.68 -1.41  606 -0.75 -0.89 -0.61 
 
Sex     0.07     0.17 
Male 301 -1.35 -1.52 -1.17  299 -0.72 -0.90 -0.54  
Female 310 -1.58 -1.75 -1.41  309 -0.78 -0.96 -0.60  
Age group     <0.001     <0.001 
6-9 years 180 -0.92 -1.16 -0.68  113 -0.25 -0.55 0.05  
10-13 years 118 -1.04 -1.31 -0.76  136 -0.45 -0.72 -0.18  
14-17 years 105 -1.48 -1.78 -1.19  130 -0.78 -1.05 -0.50  
18-21 years 51 -1.56 -1.98 -1.13  63 -0.56 -0.96 -0.17  
22-25 years 40 -1.63 -2.11 -1.14  47 -0.72 -1.19 -0.26  
26-29 years 30 -2.10 -2.65 -1.54  28 -1.13 -1.73 -0.53  
30-33 years 17 -3.07 -3.80 -2.34  17 -1.55 -2.31 -0.80  
34-37 years 14 -3.08 -3.88 -2.28  16 -2.01 -2.79 -1.23  
38-41 years 10 -2.64 -3.59 -1.68  9 -0.99 -2.04 0.05  
42-45 years 12 -3.47 -4.35 -2.60  9 -3.07 -4.12 -2.02  
46-49 years 10 -2.93 -3.89 -1.98  13 -2.43 -3.32 -1.55  
≥50 years 24 -2.18 -2.80 -1.56  27 -1.37 -1.98 -0.77  
Country     <0.001     <0.001 
Australia 31 -1.86 -2.40 -1.32  31 -1.11 -1.67 -0.55  
Belgium 58 -1.21 -1.62 -0.81  58 0.00 -0.42 0.41  
Cyprus 22 -1.78 -2.42 -1.14  22 -1.64 -2.33 -0.96  
Denmark 45 -0.95 -1.41 -0.50  45 -0.21 -0.67 0.25  
France 46 -1.27 -1.72 -0.83  46 -0.50 -0.97 -0.04  
Germany 58 -1.36 -1.76 -0.97  55 -0.66 -1.08 -0.23  
Israel 50 -1.34 -1.77 -0.91  49 -0.91 -1.35 -0.46  
Italy 33 -1.25 -1.78 -0.73  33 -0.61 -1.16 -0.06  
Netherlands 35 -0.21 -0.72 0.29  35 0.90 0.38 1.43  
Norway 12 -1.44 -2.30 -0.58  12 -0.78 -1.68 0.12  
Poland 28 -2.20 -2.77 -1.63  28 -1.30 -1.89 -0.71  
Serbia 2 -1.77 -3.88 0.35  2 -2.41 -4.61 -0.21  
Switzerland 24 -1.48 -2.11 -0.86  24 -1.05 -1.69 -0.42  
Turkey 7 -2.31 -3.45 -1.18  7 -2.28 -3.45 -1.10  
UK 160 -1.86 -2.11 -1.61   161 -1.19 -1.44 -0.94   
Mean z-scores (95%CI) for each group after adjusting for the remaining characteristics 
¶ Likelihood ratio test p-value indicating whether the characteristic explains differences in FEV1 or FVC 
within the study population 
+ Defined as hallmark PCD electron microscopy findings and/or biallelic gene mutation identified based 
on the ERS PCD Diagnostics Task Force guidelines [26] 
# Abnormal light or high frequency video microscopy finding and/or low nasal NO value 
  
Table S6. FEV1 and FVC of PCD patients of the iPCD Cohort using the latest available 
measurement instead of the earliest compared to GLI 2012 references (sensitivity analysis) (N=991) 
    FEV1   FVC 
Characteristic N mean  z-score 95% CI p-value
¶ N mean  z-score 95% CI p-value
¶ 
Total 991 -1.53 -1.63 -1.42  981 -0.77 -0.88 -0.67 
 
Sex     0.11     0.26 
Male 487 -1.45 -1.59 -1.31  483 -0.71 -0.85 -0.56  
Female 504 -1.61 -1.74 -1.47  498 -0.83 -0.97 -0.68  
Age group     <0.001     <0.001 
6-9 years 185 -0.80 -1.03 -0.57  187 -0.25 -0.48 -0.01  
10-13 years 237 -1.12 -1.32 -0.92  232 -0.53 -0.74 -0.31  
14-17 years 204 -1.55 -1.77 -1.33  200 -0.80 -1.02 -0.57  
18-21 years 107 -1.54 -1.84 -1.25  107 -0.64 -0.95 -0.33  
22-25 years 59 -1.68 -2.09 -1.28  57 -0.58 -1.00 -0.15  
26-29 years 45 -2.24 -2.70 -1.77  44 -1.20 -1.69 -0.71  
30-33 years 31 -2.65 -3.21 -2.09  32 -1.68 -2.25 -1.11  
34-37 years 27 -2.82 -3.42 -2.23  26 -1.74 -2.36 -1.11  
38-41 years 15 -2.56 -3.36 -1.76  15 -1.31 -2.14 -0.49  
42-45 years 20 -3.15 -3.85 -2.46  20 -2.54 -3.26 -1.83  
46-49 years 20 -3.07 -3.77 -2.37  21 -2.24 -2.95 -1.53  
≥50 years 41 -2.39 -2.88 -1.90  40 -1.38 -1.89 -0.87  
Country     <0.001     <0.001 
Australia 34 -1.83 -2.36 -1.30  34 -0.99 -1.54 -0.44  
Belgium 69 -1.18 -1.56 -0.81  69 -0.07 -0.46 0.32  
Cyprus 27 -1.67 -2.28 -1.07  27 -1.62 -2.24 -0.99  
Denmark 74 -1.29 -1.65 -0.93  74 -0.21 -0.59 0.16  
France 75 -1.44 -1.80 -1.07  72 -0.61 -1.00 -0.23  
Germany 142 -1.43 -1.69 -1.16  137 -0.82 -1.10 -0.55  
Israel 87 -1.58 -1.91 -1.25  84 -1.10 -1.45 -0.75  
Italy 35 -1.46 -1.99 -0.94  35 -0.63 -1.17 -0.08  
Netherlands 66 -0.62 -1.00 -0.24  66 0.54 0.14 0.93  
Norway 14 -1.21 -2.03 -0.39  14 -0.78 -1.63 0.07  
Poland 74 -1.89 -2.26 -1.53  74 -0.96 -1.34 -0.58  
Serbia 7 -2.08 -3.25 -0.92  7 -2.35 -3.56 -1.14  
Switzerland 40 -1.61 -2.10 -1.12  40 -0.77 -1.27 -0.26  
Turkey 29 -1.75 -2.34 -1.16  29 -1.51 -2.12 -0.89  
UK 218 -1.85 -2.06 -1.64  219 -1.13 -1.35 -0.91  
Diagnostic certainty     0.71     0.78 
Definite PCD diagnosis+ 611 -1.55 -1.68 -1.42  608 -0.77 -0.90 -0.63  
Probable PCD diagnosis# 207 -1.54 -1.76 -1.32  203 -0.83 -1.06 -0.60  
Clinical diagnosis only 173 -1.43 -1.68 -1.18   170 -0.70 -0.97 -0.44   
Mean z-scores (95%CI) for each group after adjusting for the remaining characteristics 
¶ Likelihood ratio test p-value indicating whether the characteristic explains differences in FEV1 or FVC 
within the study population 
+ Defined as hallmark PCD electron microscopy findings and/or biallelic gene mutation identified based 
on the ERS PCD Diagnostics Task Force guidelines [26] 
# Abnormal light or high frequency video microscopy finding and/or low nasal NO value 
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Table 1. Characteristics of the study population (N=991) 
Characteristic n % 
Sex   
Male 487 49 
Female 504 51 
Country of residence*   
Australia 34 3 
Northern Europe  306 31 
Western Europe 392 40 
Eastern Europe  74 8 
Southern Europe  42 4 
Western Asia 143 14 
Organ laterality   
Situs solitus  499 51 
Situs inversus 348 35 
Heterotaxia 13 1 
Situs status not reported 131 13 
Time period of birth   
Earlier than 1976 151 15 
1977-1996 363 37 
1997-2015 477 48 
Diagnostic information   
Definite PCD diagnosis+  611 62 
Probable PCD diagnosis# 207 21 
Clinical diagnosis only 173 17 
Age at diagnosis   
0-9 years 448 45 
10-19 years 317 32 
20-29 years 98 10 
30-39 years 61 6 
40-49 years 36 4 
≥50 years 31 3 
BMI¶   
Underweight 59 6 
Normal 752 81 
Overweight 116 13 
 
* Based on geographical region definitions of the United Nations Statistics Division (March 2017). Northern Europe: 
Denmark, Norway, United Kingdom; Western Europe: Belgium, France, Germany, Switzerland, the Netherlands; Eastern 
Europe: Poland; Southern Europe: Italy, Serbia; Western Asia: Cyprus, Israel, Turkey. + Defined as hallmark PCD 
electron microscopy findings and/or biallelic gene mutation identified based on the ERS PCD Diagnostics Guidelines [21]. 
# Abnormal light or high frequency video microscopy finding and/or low (≤ 77nl/min) nasal NO value.  
¶ BMI z-scores <=-1.96 underweight, >-1.96 & <1.96 normal, >=1.96 overweight. 
 
  
Table 2. FEV1 and FVC in patients with primary ciliary dyskinesia from the iPCD Cohort, compared 
to GLI 2012 references (N=991) 
    FEV1   FVC 
Characteristic N mean  z-score 95% CI 
p-
value* N 
mean  
z-score 95% CI p-value* 
Total 991 -1.52 -1.62 -1.41  981 -0.77 -0.88 -0.66 
 
Sex     0.03     0.20 
Male 487 -1.36 -1.49 -1.22  483 -0.70 -0.84 -0.56  
Female 504 -1.57 -1.70 -1.43  498 -0.83 -0.97 -0.69  
Age group     <0.001     <0.001 
6-9 years 271 -0.84 -1.03 -0.65  272 -0.31 -0.51 -0.11  
10-13 years 207 -1.00 -1.21 -0.79  203 -0.48 -0.70 -0.26  
14-17 years 191 -1.51 -1.73 -1.29  186 -0.84 -1.07 -0.61  
18-21 years 81 -1.71 -2.05 -1.37  82 -0.72 -1.07 -0.37  
22-25 years 55 -1.70 -2.12 -1.29  53 -0.73 -1.17 -0.29  
26-29 years 41 -2.19 -2.67 -1.72  40 -1.16 -1.66 -0.66  
30-33 years 28 -3.14 -3.71 -2.56  28 -1.91 -2.51 -1.31  
34-37 years 27 -2.87 -3.45 -2.28  25 -2.10 -2.72 -1.47  
38-41 years 17 -2.72 -3.45 -1.98  17 -1.51 -2.27 -0.75  
42-45 years 23 -3.03 -3.66 -2.39  24 -2.23 -2.87 -1.58  
46-49 years 15 -2.87 -3.66 -2.08  16 -2.02 -2.81 -1.24  
≥50 years 35 -2.30 -2.82 -1.78  35 -1.45 -1.99 -0.91  
Country     <0.001     <0.001 
Australia 34 -1.87 -2.39 -1.34  34 -1.26 -1.80 -0.72  
Belgium 69 -1.11 -1.49 -0.74  69 -0.03 -0.42 0.36  
Cyprus 27 -1.84 -2.43 -1.25  27 -1.81 -2.42 -1.20  
Denmark 74 -1.19 -1.55 -0.82  74 -0.58 -0.95 -0.20  
France 75 -1.30 -1.66 -0.94  72 -0.36 -0.74 0.02  
Germany 142 -1.36 -1.62 -1.10  137 -0.79 -1.06 -0.52  
Israel 87 -1.53 -1.86 -1.20  84 -1.08 -1.43 -0.74  
Italy 35 -1.29 -1.81 -0.78  35 -0.35 -0.89 0.18  
Netherlands 66 -0.39 -0.77 -0.02  66 0.74 0.35 1.13  
Norway 14 -1.42 -2.23 -0.61  14 -1.00 -1.83 -0.16  
Poland 74 -1.84 -2.20 -1.48  74 -0.91 -1.28 -0.54  
Serbia 7 -2.22 -3.36 -1.07  7 -2.38 -3.56 -1.19  
Switzerland 40 -1.69 -2.17 -1.20  40 -1.05 -1.55 -0.55  
Turkey 29 -1.72 -2.30 -1.14  29 -1.50 -2.10 -0.90  
UK 218 -1.78 -2.00 -1.57  219 -1.11 -1.33 -0.89  
Diagnostic certainty     0.52     0.23 
Definite PCD diagnosis+ 611 -1.47 -1.59 -1.34  608 -0.74 -0.87 -0.60  
Probable PCD 
diagnosis# 207 -1.55 -1.76 -1.33  203 -0.94 -1.16 -0.71  
Clinical diagnosis only 173 -1.36 -1.60 -1.11   170 -0.67 -0.93 -0.41   
Mean z-scores (95%CI) for each group after adjusting for the remaining characteristics. * likelihood ratio test p-value 
indicating whether the characteristic explains differences in FEV1 within the study population. + defined as hallmark PCD 
electron microscopy findings and/or biallelic gene mutation identified based on the ERS PCD Diagnostics Guidelines [25].  
# abnormal light or high frequency video microscopy finding and/or low nasal NO value 
  
Table 3. FEV1 and FVC of PCD patients of the iPCD Cohort with available ultrastructural defect 
information compared to GLI 2012 references 
  FEV1  FVC 
Characteristic N mean z-score 95% CI p-value
¶ N mean z-score 95% CI p-value
¶ 
Total 689 -1.52 -1.65 -1.40  683 -0.79 -0.92 -0.66  
Sex 
    
0.25 
    
0.52 
Male 344 -1.46 -1.62 -1.29 
 
341 -0.76 -0.93 -0.58 
 
Female 345 -1.59 -1.75 -1.43 
 
342 -0.83 -1.00 -0.66 
 
Age group 
    
<0.001 
    
<0.001 
6-9 years 127 -0.77 -1.04 -0.49 
 
126 -0.25 -0.54 0.03 
 
10-13 years 148 -1.19 -1.44 -0.94 
 
147 -0.65 -0.91 -0.39 
 
14-17 years 152 -1.51 -1.76 -1.26 
 
151 -0.84 -1.10 -0.58 
 
18-21 years 69 -1.53 -1.89 -1.17 
 
68 -0.62 -1.00 -0.23 
 
22-25 years 51 -1.66 -2.09 -1.23 
 
50 -0.61 -1.05 -0.16 
 
26-29 years 35 -2.14 -2.66 -1.63 
 
34 -1.17 -1.71 -0.63 
 
30-33 years 23 -2.47 -3.10 -1.84 
 
22 -1.42 -2.09 -0.76 
 
34-37 years 20 -2.67 -3.34 -1.99 
 
21 -1.74 -2.43 -1.06 
 
38-41 years 10 -2.37 -3.33 -1.41 
 
10 -1.00 -2.00 -0.01 
 
42-45 years 10 -3.24 -4.20 -2.28 
 
11 -2.86 -3.81 -1.91 
 
46-49 years 17 -3.00 -3.74 -2.25 
 
16 -2.05 -2.84 -1.25 
 
≥50 years 27 -2.34 -2.93 -1.75 
 
27 -1.29 -1.90 -0.68 
 
Country 
    
<0.001 
    
<0.001 
Australia 31 -1.82 -2.36 -1.28 
 
31 -1.18 -1.74 -0.62 
 
Belgium 66 -1.20 -1.59 -0.82 
 
66 0.03 -0.36 0.43 
 
Cyprus 27 -2.02 -2.62 -1.43 
 
27 -1.79 -2.40 -1.17 
 
Denmark 23 -1.36 -1.99 -0.72 
 
23 -0.60 -1.26 0.05 
 
France 59 -1.28 -1.68 -0.87 
 
59 -0.45 -0.87 -0.03 
 
Germany 83 -1.21 -1.54 -0.87 
 
79 -0.69 -1.05 -0.33 
 
Israel 67 -1.46 -1.83 -1.08 
 
64 -0.89 -1.28 -0.49 
 
Italy 35 -1.46 -1.98 -0.95 
 
35 -0.65 -1.19 -0.12 
 
Netherlands 30 -0.45 -1.01 0.11 
 
30 0.66 0.08 1.24 
 
Norway 13 -1.43 -2.27 -0.60 
 
13 -0.84 -1.71 0.03 
 
Poland 39 -1.80 -2.30 -1.30 
 
39 -0.89 -1.41 -0.37 
 
Serbia 2 -1.77 -3.97 0.44 
 
2 -2.39 -4.68 -0.11 
 
Switzerland 24 -1.45 -2.10 -0.81 
 
24 -0.83 -1.50 -0.16 
 
Turkey 7 -2.12 -3.28 -0.96 
 
7 -2.13 -3.33 -0.92 
 
UK 183 -1.90 -2.13 -1.67 
 
184 -1.19 -1.43 -0.96 
 
Ultrastructural defect* 
    
0.01 
    
0.18 
Non-diagnostic 123 -1.19 -1.48 -0.91 
 
120 -0.74 -1.04 -0.44 
 
Dynein arm defects 425 -1.50 -1.65 -1.35 
 
422 -0.73 -0.88 -0.57 
 
Microtubular defects  134 -1.91 -2.20 -1.63 
 
134 -1.08 -1.37 -0.78 
 
Acilia 7 -1.44 -2.64 -0.24   7 -0.40 -1.64 0.85   
Mean z-scores (95%CI) for each group after adjusting for the remaining characteristics 
¶ Likelihood ratio test p-value indicating whether the characteristic explains differences in FEV1 or FVC 
within the study population 
+ Defined as hallmark PCD electron microscopy findings and/or biallelic gene mutation identified based on 
the ERS PCD Diagnostics Task Force guidelines [26] 
# Abnormal light or high frequency video microscopy finding and/or low nasal NO value 
* Dynein arm defects: Outer and/or inner dynein arm defects, Microtubular defects: central pair, tubulus disorganisation, 
tubular transposition and/or nexin link defect. 
